Last reviewed · How we verify
analogous oseltamivir phosphate capsule
Oseltamivir phosphate is a prodrug that is metabolized to oseltamivir carboxylate, which acts as a potent inhibitor of influenza virus neuraminidase.
Oseltamivir phosphate is a prodrug that is metabolized to oseltamivir carboxylate, which acts as a potent inhibitor of influenza virus neuraminidase. Used for Treatment and prophylaxis of influenza A and B in patients 1 year and older, Treatment of acute uncomplicated influenza in patients 2 weeks of age and older.
At a glance
| Generic name | analogous oseltamivir phosphate capsule |
|---|---|
| Also known as | analogous oseltamivir phosphate capsule,0221503013 |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University |
| Drug class | Neuraminidase inhibitor |
| Target | Neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Oseltamivir carboxylate binds to the active site of neuraminidase, preventing the release of newly formed viral particles from infected cells. This action inhibits the spread of influenza virus within the body, thereby reducing the severity and duration of symptoms.
Approved indications
- Treatment and prophylaxis of influenza A and B in patients 1 year and older
- Treatment of acute uncomplicated influenza in patients 2 weeks of age and older
Common side effects
- Nausea
- Vomiting
- Headache
- Fatigue
- Diarrhea
Key clinical trials
- Phase IIaTrials of GanMaoKangNing Granules (PHASE2)
- Lingdancao Granules in the Treatment of Seasonal Influenza (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: